Dysfunctional HDL: A novel important diagnostic and therapeutic target in cardiovascular disease?

Otocka-Kmiecik, Aneta; Mikhailidis, Dimitri P.; Nicholls, Stephen J.; Davidson, Michael; Rysz, Jacek; Banach, Maciej

doi:10.1016/j.plipres.2012.03.003

Cited by 194 publications

(159 citation statements)

References 123 publications

Supporting

Mentioning

137

Contrasting

Unclassified

Order By: Relevance

“…Systemic oxidative stress and inflammation are major contributors to the pathogenesis of CKD-associated abnormalities in HDL structure and function [92][93][94] .…”

Section: Srb1mentioning

confidence: 99%

HDL abnormalities in nephrotic syndrome and chronic kidney disease

2015

View full text Add to dashboard Cite

| Normal HDL activity confers cardiovascular and overall protection by mediating reverse cholesterol transport and through its potent anti-inflammatory, antioxidant, and antithrombotic functions. Serum lipid profile, as well as various aspects of HDL metabolism, structure, and function can be profoundly altered in patients with nephrotic range proteinuria or chronic kidney disease (CKD). These abnormalities can, in turn, contribute to the progression of cardiovascular complications and various other comorbidities, such as foam cell formation, atherosclerosis, and/or glomerulosclerosis, in affected patients. The presence and severity of proteinuria and renal insufficiency, as well as dietary and drug regimens, pre-existing genetic disorders of lipid metabolism, and renal replacement therapies (including haemodialysis, peritoneal dialysis, and renal transplantation) determine the natural history of lipid disorders in patients with kidney disease. Despite the adverse effects associated with dysregulated reverse cholesterol transport and advances in our understanding of the underlying mechanisms, safe and effective therapeutic interventions are currently lacking. This Review provides an overview of HDL metabolism under normal conditions, and discusses the features, mechanisms, and consequences of HDL abnormalities in patients with nephrotic syndrome or advanced CKD.

show abstract

“…Systemic oxidative stress and inflammation are major contributors to the pathogenesis of CKD-associated abnormalities in HDL structure and function [92][93][94] .…”

Section: Srb1mentioning

confidence: 99%

HDL abnormalities in nephrotic syndrome and chronic kidney disease

2015

View full text Add to dashboard Cite

show abstract

“…in alirocumab group as compared to placebo group [20]. These results are very important taking into account the continuing discussion on the role of different subfractions/ subpopulations on LDL-C and HDL-C (as well socalled dysfunctional HDL) on the progression of atherosclerosis [21][22][23][24][25].…”

Section: What Next After Approval Of the Pcsk9 Inhibitors?mentioning

confidence: 97%

Lipids, blood pressure and kidney update 2014

Banach

Aronow

Şerban

et al. 2015

Pharmacological Research

Self Cite

View full text Add to dashboard Cite

“…Therefore, it would be still highly interesting to observe all patients for next several years, using available imaging methods, and to evaluate early markers of atherosclerosis, including sensitive markers of inflammation and stress oxidation (dysfunctional HDL (124), subfractions and subpopulations of LDL-C/HDL-C (125), endocan (126), GlycA, GlycB, endothelium function -(NO, O2-and ONOO-measurements) (127), miRNA: miR-221, miR-155, miR-100 and hsa-miR-1273 (128)). Thus far, the optimal duration of dual-antiplatelet therapy after BRS implant is unclear and has not been investigated.…”

Section: Future Perspectivementioning

confidence: 99%

Bioresorbable scaffold — A magic bullet for the treatment of coronary artery disease?

Brie

Penson

Şerban

et al. 2016

International Journal of Cardiology

Self Cite

View full text Add to dashboard Cite

ABSTRACT:Today, drug-eluting metal stents are considered the gold standard for interventional treatment of coronary artery disease. While providing inhibition of neointimal hyperplasia, drug-eluting metal stents have many limitations such as the risk of late and very late stent thrombosis, restriction of vascular vasomotion and chronic local inflammatory reaction due to permanent implantation of a 'metallic cage', recognized as a foreign body. Bioresorbable scaffold stents (BRS) are a new solution, which is trying to overcome the limitation of the 'metallic cage'. This structure provides short-term scaffolding of the vessel and then disappears, leaving nothing behind. The purpose of this review is to present the theoretical rationale for the use of BRS and to outline the clinical outcomes associated with their use in terms of data obtained from RCTs, clinical trials, registries and real life use. We have also tried to answer all questions on this intervention based on available data, with a focus on ABSORB BVS (Abbott Vascular, Santa Clara, USA). We consider that this new technology can be the "magic bullet" to treat coronary artery disease.

show abstract

Dysfunctional HDL: A novel important diagnostic and therapeutic target in cardiovascular disease?

Cited by 194 publications

References 123 publications

HDL abnormalities in nephrotic syndrome and chronic kidney disease

HDL abnormalities in nephrotic syndrome and chronic kidney disease

Lipids, blood pressure and kidney update 2014

Bioresorbable scaffold — A magic bullet for the treatment of coronary artery disease?

Contact Info

Product

Resources

About